Skip to main content
Top
Published in: Rheumatology International 12/2016

01-12-2016 | Imaging

Anti-CCP status determines the power Doppler oscillation pattern in rheumatoid arthritis: a prospective study

Authors: Ottar Gadeholt, Tobias Wech, Sebastian Schuh, Eva Scharbatke, Eva Ostermeier, Hans-Peter Tony, Marc Schmalzing

Published in: Rheumatology International | Issue 12/2016

Login to get access

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction. Serologically, it can be differentiated according to rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP), or both. This differentiation is prognostically and therapeutically relevant. No method has been described to separate the two forms phenotypically. We hypothesize that a differentiation is possible by evaluating oscillation patterns in power Doppler sonography (PDS). In a prospective study, 20 patients with anti-CCP-positive RA and 20 patients with anti-CCP-negative RA with active wrist synovitis were examined. A PDS scan was performed, and perfusion maxima (P max) and minima (P min) as well as the amplitude (ΔP) were determined by a blinded study member. The amplitude was standardized (sΔP) by dividing by P max, and the anti-CCP-positive and anti-CCP-negative patients as well as the RF-positive and RF-negative were compared to each other. In the ultrasonographic evaluation, we found a highly significant difference in sΔP between CCPp and CCPn patients (median 19.0 vs. 42.9 %, p < 0.0001). sΔP is independent of disease activity. The absolute amplitude ΔP did not differ between the groups. Also, in anti-CCP-positive patients there was a completely linear correlation between P max and P min, and this was far less marked in anti-CCP-negative patients. Anti-CCP-positive and anti-CCP-negative RA display different PDS oscillation patterns. This constitutes a nonserological parameter to differentiate between the two forms. The difference in PDS oscillation patterns suggests that the underlying pathological process differs between the forms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Hawker G et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 69:1580e8 Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Hawker G et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 69:1580e8
2.
go back to reference Van Venrooij W, Zendman A (2008) Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis. Clinic Rev Allergy Immunol 34:36–39CrossRef Van Venrooij W, Zendman A (2008) Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis. Clinic Rev Allergy Immunol 34:36–39CrossRef
3.
go back to reference Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Barton A et al (2007) The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 56:2929–2935CrossRefPubMedPubMedCentral Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Barton A et al (2007) The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 56:2929–2935CrossRefPubMedPubMedCentral
4.
go back to reference Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Read SJ et al (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72:329–336CrossRefPubMed Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Read SJ et al (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72:329–336CrossRefPubMed
5.
go back to reference Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54:1117–1121CrossRefPubMed Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54:1117–1121CrossRefPubMed
6.
go back to reference Verpoort KN, van Gaalen FA, Van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Toes RE et al (2005) Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 52:3058–3062CrossRefPubMed Verpoort KN, van Gaalen FA, Van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Toes RE et al (2005) Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 52:3058–3062CrossRefPubMed
7.
go back to reference Terao C, Yamakawa N, Yano K, Markusse IM, Ikari K, Matsuda F et al (2015) Rheumatoid factor is associated with the distribution of hand joint destruction in rheumatoid arthritis. Arthritis Rheum 67:3113–3123CrossRef Terao C, Yamakawa N, Yano K, Markusse IM, Ikari K, Matsuda F et al (2015) Rheumatoid factor is associated with the distribution of hand joint destruction in rheumatoid arthritis. Arthritis Rheum 67:3113–3123CrossRef
8.
go back to reference Ohmdorf S, Backhaus M (2015) Pro musculoskeletal ultrasonography in rheumatoid arthritis. Clin Exp Rheumatol 33(Suppl. 92):50–53 Ohmdorf S, Backhaus M (2015) Pro musculoskeletal ultrasonography in rheumatoid arthritis. Clin Exp Rheumatol 33(Suppl. 92):50–53
9.
go back to reference Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Østergaard M (2003) Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum 48:955–962CrossRefPubMed Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Østergaard M (2003) Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum 48:955–962CrossRefPubMed
10.
go back to reference Schmidt WA, Schönau V, Reiche BE, Oberdorfer PE, Ohmdorf S, Backhaus M (2015) Grading of ultrasound Doppler signals in synovitis: Does it need an update? Rheumatology 54:1897–1903CrossRefPubMed Schmidt WA, Schönau V, Reiche BE, Oberdorfer PE, Ohmdorf S, Backhaus M (2015) Grading of ultrasound Doppler signals in synovitis: Does it need an update? Rheumatology 54:1897–1903CrossRefPubMed
11.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed
12.
go back to reference Hau M, Kneitz C, Tony HP, Keberle M, Jahns R, Jenett M (2002) High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). Ann Rheum Dis 61:55–58CrossRefPubMedPubMedCentral Hau M, Kneitz C, Tony HP, Keberle M, Jahns R, Jenett M (2002) High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). Ann Rheum Dis 61:55–58CrossRefPubMedPubMedCentral
13.
go back to reference Schueller-Weidekamm C, Krestan C, Schueller G, Kapral T, Aletaha D, Kainberger F (2007) Power Doppler sonography and pulse-inversion harmonic imaging in evaluation of rheumatoid arthritis synovitis. AJR Am J Roentgenol 188:504–508CrossRefPubMed Schueller-Weidekamm C, Krestan C, Schueller G, Kapral T, Aletaha D, Kainberger F (2007) Power Doppler sonography and pulse-inversion harmonic imaging in evaluation of rheumatoid arthritis synovitis. AJR Am J Roentgenol 188:504–508CrossRefPubMed
14.
go back to reference Litwin SD, Singer JM (1965) Studies of the incidence and significance of anti gamma globulin factors in the aging. Arthritis Rheum 8:538–550CrossRefPubMed Litwin SD, Singer JM (1965) Studies of the incidence and significance of anti gamma globulin factors in the aging. Arthritis Rheum 8:538–550CrossRefPubMed
15.
go back to reference Kelly S, Bombardieri M, Humby F, Ng N, Marelli A, Pitzalis C et al (2015) Angiogenic gene expression and vascular density are reflected in ultrasonographic features of synovitis in early rheumatoid arthritis: an observational study. Arthritis Res Ther 17:58CrossRefPubMedPubMedCentral Kelly S, Bombardieri M, Humby F, Ng N, Marelli A, Pitzalis C et al (2015) Angiogenic gene expression and vascular density are reflected in ultrasonographic features of synovitis in early rheumatoid arthritis: an observational study. Arthritis Res Ther 17:58CrossRefPubMedPubMedCentral
Metadata
Title
Anti-CCP status determines the power Doppler oscillation pattern in rheumatoid arthritis: a prospective study
Authors
Ottar Gadeholt
Tobias Wech
Sebastian Schuh
Eva Scharbatke
Eva Ostermeier
Hans-Peter Tony
Marc Schmalzing
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3548-6

Other articles of this Issue 12/2016

Rheumatology International 12/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.